ZA200704909B - Method of treatment or prophylaxis - Google Patents
Method of treatment or prophylaxisInfo
- Publication number
- ZA200704909B ZA200704909B ZA2007/04909A ZA200704909A ZA200704909B ZA 200704909 B ZA200704909 B ZA 200704909B ZA 2007/04909 A ZA2007/04909 A ZA 2007/04909A ZA 200704909 A ZA200704909 A ZA 200704909A ZA 200704909 B ZA200704909 B ZA 200704909B
- Authority
- ZA
- South Africa
- Prior art keywords
- prophylaxis
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004907332A AU2004907332A0 (en) | 2004-12-24 | Method of Treatment or Prophylaxis | |
| PCT/AU2005/001975 WO2006066361A1 (en) | 2004-12-24 | 2005-12-23 | Method of treatment or prophylaxis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200704909B true ZA200704909B (en) | 2012-12-27 |
Family
ID=36601295
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2007/04909A ZA200704909B (en) | 2004-12-24 | 2007-06-20 | Method of treatment or prophylaxis |
| ZA2012/07323A ZA201207323B (en) | 2004-12-24 | 2012-10-01 | Method of treatment of prophylaxis |
| ZA2012/07322A ZA201207322B (en) | 2004-12-24 | 2012-10-01 | Method of treatment of prophylaxis |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/07323A ZA201207323B (en) | 2004-12-24 | 2012-10-01 | Method of treatment of prophylaxis |
| ZA2012/07322A ZA201207322B (en) | 2004-12-24 | 2012-10-01 | Method of treatment of prophylaxis |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7795275B2 (enExample) |
| EP (3) | EP1830869B1 (enExample) |
| JP (1) | JP4966202B2 (enExample) |
| CN (3) | CN101087619B (enExample) |
| CY (1) | CY1114424T1 (enExample) |
| DK (1) | DK1830869T3 (enExample) |
| ES (1) | ES2425567T3 (enExample) |
| HR (1) | HRP20130738T1 (enExample) |
| ME (1) | ME01597B (enExample) |
| NZ (1) | NZ555334A (enExample) |
| PL (1) | PL1830869T3 (enExample) |
| PT (1) | PT1830869E (enExample) |
| RS (1) | RS52927B (enExample) |
| SI (1) | SI1830869T1 (enExample) |
| WO (1) | WO2006066361A1 (enExample) |
| ZA (3) | ZA200704909B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| AU2007229322B2 (en) * | 2006-03-20 | 2012-04-05 | Novartis Ag | Method of treatment or prophylaxis inflammatory pain |
| JP2010505881A (ja) * | 2006-10-05 | 2010-02-25 | ギリアード・パロ・アルト・インコーポレイテッド | ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物 |
| US20090105283A1 (en) * | 2007-04-11 | 2009-04-23 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| JP2012505881A (ja) * | 2008-10-15 | 2012-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体 |
| US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| CA2787173C (en) * | 2010-01-19 | 2018-05-01 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| DE102010013075A1 (de) | 2010-03-26 | 2011-09-29 | B. Braun Melsungen Ag | Antimikrobielle Wundauflage |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| CN103003244B (zh) * | 2010-07-21 | 2016-04-20 | 诺华股份有限公司 | 四氢异喹啉衍生物的盐和溶剂合物 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN108707151B (zh) | 2011-08-23 | 2022-06-03 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| PT2800738T (pt) | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| CN104470930B (zh) | 2012-01-25 | 2017-02-22 | 诺华股份有限公司 | 杂环化合物和它们的使用方法 |
| US20150011565A1 (en) | 2012-01-25 | 2015-01-08 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic Compounds and Methods For Their Use |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| US9714224B2 (en) | 2013-07-08 | 2017-07-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| AU2014324442B2 (en) | 2013-09-30 | 2018-06-14 | Fmc Corporation | Foam formulations and apparatus for delivery |
| WO2015109210A1 (en) | 2014-01-17 | 2015-07-23 | Cardioxyl Pharmaceuticals, Inc. | N-hydroxymethanesulfonamide nitroxyl donors |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| UY36181A (es) | 2014-06-24 | 2016-09-30 | Fmc Corp | Formulaciones de espumas y concentrados emulsionables |
| EP3245198B1 (en) | 2015-01-13 | 2020-03-11 | Novartis AG | Pyrrolidine derivatives as angiotensin ii type 2 antagonists |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10308628B2 (en) | 2015-03-12 | 2019-06-04 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| KR102691777B1 (ko) | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| US11632959B2 (en) | 2015-12-23 | 2023-04-25 | Fmc Corporation | In situ treatment of seed in furrow |
| US20190152918A1 (en) | 2016-06-27 | 2019-05-23 | Ratiopharm Gmbh | Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid |
| JP2019514862A (ja) | 2017-03-23 | 2019-06-06 | ノバルティス アーゲー | （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形 |
| US20190008868A1 (en) | 2017-04-28 | 2019-01-10 | Asana Biosciences, Llc | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient |
| PT3620454T (pt) * | 2017-06-09 | 2021-09-10 | Shandong Danhong Pharmaceutical Co Ltd | Derivado de ácido carboxílico como antagonista do recetor at2r |
| GB201710906D0 (en) * | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| AU2019223882B2 (en) | 2018-02-23 | 2023-01-12 | Beijing Tide Pharmaceutical Co., Ltd. | Receptor inhibitors, pharmaceutical compositions comprising the same, and usage thereof |
| EP3770148B1 (en) | 2018-03-23 | 2024-10-02 | Beijing Tide Pharmaceutical Co., Ltd. | Receptor inhibitor, pharmaceutical composition comprising same, and use thereof |
| EP3820498A1 (en) * | 2018-06-14 | 2021-05-19 | University College Cork-National University of Ireland Cork | Peptide for disease treatment |
| WO2020012266A1 (en) | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
| MX2024001155A (es) | 2021-07-30 | 2024-07-01 | Confo Therapeutics N V | Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r. |
| CN119585241A (zh) | 2022-05-17 | 2025-03-07 | 伊莱利利公司 | At2r拮抗剂及其用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3531485A (en) * | 1967-08-14 | 1970-09-29 | American Home Prod | Aryl-substituted diazabicycloalkanes |
| US3957795A (en) * | 1974-01-28 | 1976-05-18 | Delmar Chemicals Limited | Novel cyclopentene and cyclopentane derivatives |
| US3975795A (en) | 1975-01-20 | 1976-08-24 | Union Carbide Corporation | Product stuffing apparatus and method |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| US5091390A (en) | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| CA2093125C (en) | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
| US5385894A (en) | 1991-03-06 | 1995-01-31 | Merck & Co., Inc. | Disubstituted 6-aminoquinazolinones |
| US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| US5292726A (en) | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| GB9208116D0 (en) | 1992-04-13 | 1992-05-27 | Ici Plc | Therapeutic agents |
| EP0636027B1 (en) | 1992-04-13 | 1999-07-07 | Zeneca Limited | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5344830A (en) | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| CA2151380A1 (en) * | 1992-12-11 | 1994-06-23 | Peter Buhlmayer | Substituted benzazepinones |
| US5395844A (en) | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| AP9400651A0 (en) | 1993-07-15 | 1995-12-30 | Pfizer | Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists. |
| US5409926A (en) | 1993-07-19 | 1995-04-25 | Merck & Co., Inc. | AT-2 antagonist inhibition of vascular restenosis |
| US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| FR2739625B1 (fr) | 1995-10-09 | 1997-12-05 | Atochem Elf Sa | Copolymeres hydrosolubles associatifs triblocs |
| GB2323783A (en) | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
| WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| US6277839B1 (en) | 1998-10-07 | 2001-08-21 | Merck Frosst Canada & Co. | Biphenylene lactams as prostaglandin receptor ligands |
| DK1588706T3 (da) * | 1998-12-23 | 2012-01-16 | Novartis Ag | Valsartantablet |
| WO2001044239A2 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| CA2393755C (en) | 1999-12-16 | 2010-09-21 | The University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20020077328A1 (en) | 2000-07-13 | 2002-06-20 | Fred Hassan | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
| IL155703A0 (en) | 2000-11-17 | 2003-11-23 | Warner Lambert Co | Treatment of sexual dysfunction with non peptide bombesin receptor antagonists |
| EG23054A (en) | 2001-01-22 | 2004-02-29 | Sankyo Co | Pyrrole derivatives their preparation and their therapeutic uses |
| CA2436361C (en) | 2001-01-29 | 2010-11-02 | Takeda Chemical Industries, Ltd. | Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent |
| US20030170222A1 (en) | 2001-01-29 | 2003-09-11 | University Of Utah Research Foundation | Beta-superfamily conotoxins |
| HUP0501017A3 (en) * | 2001-12-14 | 2010-06-28 | Targacept | Methods and compositions for treatment of central nervous system disorders |
| WO2003064414A1 (en) | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| AR038377A1 (es) | 2002-02-08 | 2005-01-12 | Merck & Co Inc | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) |
| AU2003209851A1 (en) * | 2002-03-20 | 2003-09-29 | The University Of Queensland | Method of treatment and/or prophylaxis |
| AU2003291613B2 (en) | 2002-04-30 | 2007-09-27 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| AU2003236668A1 (en) | 2002-05-17 | 2003-12-02 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| AU2003237224A1 (en) | 2002-05-29 | 2003-12-19 | Merck And Co., Inc. | 1,2 diamido cycloalkyl sodium channel blockers |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| EP2283864A1 (en) | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| PA8597401A1 (es) * | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| WO2004099248A2 (en) | 2003-05-05 | 2004-11-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2) |
| US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| NZ555334A (en) * | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
-
2005
- 2005-12-23 NZ NZ555334A patent/NZ555334A/en not_active IP Right Cessation
- 2005-12-23 US US11/315,354 patent/US7795275B2/en not_active Expired - Fee Related
- 2005-12-23 SI SI200531764T patent/SI1830869T1/sl unknown
- 2005-12-23 DK DK05821524T patent/DK1830869T3/da active
- 2005-12-23 CN CN2005800441997A patent/CN101087619B/zh not_active Expired - Fee Related
- 2005-12-23 EP EP20050821524 patent/EP1830869B1/en not_active Expired - Lifetime
- 2005-12-23 EP EP20130162564 patent/EP2650010A1/en not_active Withdrawn
- 2005-12-23 JP JP2007547106A patent/JP4966202B2/ja not_active Expired - Lifetime
- 2005-12-23 PT PT58215245T patent/PT1830869E/pt unknown
- 2005-12-23 HR HRP20130738TT patent/HRP20130738T1/hr unknown
- 2005-12-23 ME MEP-2013-88A patent/ME01597B/me unknown
- 2005-12-23 RS RSP20130354 patent/RS52927B/sr unknown
- 2005-12-23 ES ES05821524T patent/ES2425567T3/es not_active Expired - Lifetime
- 2005-12-23 EP EP20130162570 patent/EP2650011A1/en not_active Withdrawn
- 2005-12-23 WO PCT/AU2005/001975 patent/WO2006066361A1/en not_active Ceased
- 2005-12-23 CN CN201210208621.XA patent/CN102861019B/zh not_active Expired - Fee Related
- 2005-12-23 PL PL05821524T patent/PL1830869T3/pl unknown
- 2005-12-23 CN CN2010105444424A patent/CN102049048B/zh not_active Expired - Fee Related
-
2007
- 2007-06-20 ZA ZA2007/04909A patent/ZA200704909B/en unknown
-
2010
- 2010-08-03 US US12/849,727 patent/US8492382B2/en not_active Expired - Fee Related
-
2011
- 2011-06-24 US US13/167,980 patent/US8404686B2/en not_active Expired - Fee Related
-
2012
- 2012-10-01 ZA ZA2012/07323A patent/ZA201207323B/en unknown
- 2012-10-01 ZA ZA2012/07322A patent/ZA201207322B/en unknown
-
2013
- 2013-06-20 US US13/923,085 patent/US8722675B2/en not_active Expired - Fee Related
- 2013-08-13 CY CY20131100691T patent/CY1114424T1/el unknown
-
2014
- 2014-03-28 US US14/229,746 patent/US9018207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200704909B (en) | Method of treatment or prophylaxis | |
| PL2302097T3 (pl) | Metoda obróbki powierzchni | |
| EP2032131A4 (en) | Methods of Treatment | |
| IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
| ZA200808183B (en) | Method of treatment or prophylaxis of inflammatory pain | |
| GB0404656D0 (en) | Treatment of spinal conditions | |
| IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
| GB0610746D0 (en) | Method of treatment | |
| GB0302572D0 (en) | Method of treatment | |
| GB0306309D0 (en) | Method of treatment | |
| EP1737445A4 (en) | METHOD FOR TREATING DOWN SYNDROME | |
| ZA200709024B (en) | Method of well treatment and construction | |
| GB0402578D0 (en) | Methods of treatment of atherosclerosis | |
| GB0426196D0 (en) | Methods of treatment | |
| EP1809276A4 (en) | PROCESSING PROCESS | |
| GB0419175D0 (en) | Method of treatment and compositions | |
| GB0327975D0 (en) | Methods of treatment | |
| AU2004907332A0 (en) | Method of Treatment or Prophylaxis | |
| EP1793831A4 (en) | PROCESS FOR TREATMENT OR PROTECTION AGAINST LYMPHODIES | |
| GB0421176D0 (en) | Treatment of atherosclerosis | |
| GB0522330D0 (en) | Method of treatment | |
| GB0422012D0 (en) | Methods of treatment | |
| HU0400952D0 (en) | Treatment of anus-cancer | |
| AU2006901413A0 (en) | Method of treatment or prophylaxis | |
| GB0408799D0 (en) | Method of treating pain |